126 related articles for article (PubMed ID: 25896653)
1. Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity.
Ivanciu L; Camire RM
Blood; 2015 Jul; 126(1):94-102. PubMed ID: 25896653
[TBL] [Abstract][Full Text] [Related]
2. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia.
Ivanciu L; Toso R; Margaritis P; Pavani G; Kim H; Schlachterman A; Liu JH; Clerin V; Pittman DD; Rose-Miranda R; Shields KM; Erbe DV; Tobin JF; Arruda VR; Camire RM
Nat Biotechnol; 2011 Oct; 29(11):1028-33. PubMed ID: 22020385
[TBL] [Abstract][Full Text] [Related]
3. Bioengineering factor Xa to treat bleeding.
Camire RM
Thromb Res; 2016 May; 141 Suppl 2():S31-3. PubMed ID: 27207419
[TBL] [Abstract][Full Text] [Related]
4. Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro.
Bunce MW; Toso R; Camire RM
Blood; 2011 Jan; 117(1):290-8. PubMed ID: 20864578
[TBL] [Abstract][Full Text] [Related]
5. Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L).
George LA; Thalji NK; Raffini LJ; Gimotty PA; Camire RM
J Thromb Haemost; 2015 Sep; 13(9):1694-8. PubMed ID: 26190406
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXa
Parsons-Rich D; Hua F; Li G; Kantaridis C; Pittman DD; Arkin S
J Thromb Haemost; 2017 May; 15(5):931-937. PubMed ID: 28294526
[TBL] [Abstract][Full Text] [Related]
7. A rapid pro-hemostatic approach to overcome direct oral anticoagulants.
Thalji NK; Ivanciu L; Davidson R; Gimotty PA; Krishnaswamy S; Camire RM
Nat Med; 2016 Aug; 22(8):924-32. PubMed ID: 27455511
[TBL] [Abstract][Full Text] [Related]
8. Induction and Impact of Anti-Drug Responses Elicited by a Human Recombinant Coagulation Factor FXa
Parng C; Bolt M; Pittman DD; Caiazzo T; Dyleski L; Gorovits B; Webster R
AAPS J; 2019 Apr; 21(3):52. PubMed ID: 30976993
[TBL] [Abstract][Full Text] [Related]
9. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
Hoffman M; Monroe DM
Dis Mon; 2003 Jan; 49(1):14-21. PubMed ID: 12525825
[TBL] [Abstract][Full Text] [Related]
10. The conformational switch from the factor X zymogen to protease state mediates exosite expression and prothrombinase assembly.
Toso R; Zhu H; Camire RM
J Biol Chem; 2008 Jul; 283(27):18627-35. PubMed ID: 18460471
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Pharmacokinetics, Pharmacodynamics, Tissue Distribution, and Interspecies Scaling of Recombinant Human Coagulation Factor Xa
Parng C; Markiewicz V; Chen J; Leary B; Duriga N; Dyleski L; Caiazzo T; Bolt M; Joyce A; Gorovits B; Pittman DD; Webster R
J Pharm Sci; 2017 Aug; 106(8):2136-2143. PubMed ID: 28389265
[TBL] [Abstract][Full Text] [Related]
12. Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding.
Thalji NK; Camire RM
Curr Opin Hematol; 2017 Sep; 24(5):453-459. PubMed ID: 28692575
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis of the clotting defect in a bleeding patient missing the Asp-185 codon in the factor X gene.
Lu Q; Yang L; Manithody C; Wang X; Rezaie AR
Thromb Res; 2014 Nov; 134(5):1103-9. PubMed ID: 25179519
[TBL] [Abstract][Full Text] [Related]
14. Sodium binding site of factor Xa: role of sodium in the prothrombinase complex.
Rezaie AR; He X
Biochemistry; 2000 Feb; 39(7):1817-25. PubMed ID: 10677232
[TBL] [Abstract][Full Text] [Related]
15. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.
Hilden I; Lauritzen B; Sørensen BB; Clausen JT; Jespersgaard C; Krogh BO; Bowler AN; Breinholt J; Gruhler A; Svensson LA; Petersen HH; Petersen LC; Balling KW; Hansen L; Hermit MB; Egebjerg T; Friederichsen B; Ezban M; Bjørn SE
Blood; 2012 Jun; 119(24):5871-8. PubMed ID: 22563084
[TBL] [Abstract][Full Text] [Related]
16. The tissue factor/factor VIIa/factor Xa complex: a model built by docking and site-directed mutagenesis.
Norledge BV; Petrovan RJ; Ruf W; Olson AJ
Proteins; 2003 Nov; 53(3):640-8. PubMed ID: 14579355
[TBL] [Abstract][Full Text] [Related]
17. Zymogenic and enzymatic properties of the 70-80 loop mutants of factor X/Xa.
Chen L; Manithody C; Yang L; Rezaie AR
Protein Sci; 2004 Feb; 13(2):431-42. PubMed ID: 14739327
[TBL] [Abstract][Full Text] [Related]
18. Factor Xa dimerization competes with prothrombinase complex formation on platelet-like membrane surfaces.
Koklic T; Chattopadhyay R; Majumder R; Lentz BR
Biochem J; 2015 Apr; 467(1):37-46. PubMed ID: 25572019
[TBL] [Abstract][Full Text] [Related]
19. Lyso-Sulfatide Binds Factor Xa and Inhibits Thrombin Generation by the Prothrombinase Complex.
Yegneswaran S; Banerjee Y; Fernández JA; Deguchi H; Griffin JH
PLoS One; 2015; 10(8):e0135025. PubMed ID: 26263376
[TBL] [Abstract][Full Text] [Related]
20. Innovative Three-Step Microwave-Promoted Synthesis of
Santana-Romo F; Lagos CF; Duarte Y; Castillo F; Moglie Y; Maestro MA; Charbe N; Zacconi FC
Molecules; 2020 Jan; 25(3):. PubMed ID: 31979319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
